MCP
TXG icon

Meridiem Capital Partners’s 10x Genomics TXG Stock Holding History

Meridiem Capital Partners’s Portfolio TXG Stock Details TXG Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$16.2M Sell
422,219
-101,779
-19% -$2.67M 0.73% 57
2026
Q1 		$11.1M Buy
+523,998
New +$10.5M 0.73% 47
2025
Q1 		– Sell
-342,870
Closed -$4.92M – 94
2024
Q4 		$4.92M Buy
+342,870
New +$5.41M 0.43% 56

Other funds holding TXG

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
QCM
Quantinno Capital Management New York $83.3B AUM 37.97% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Meridiem Capital Partners's TXG Position: Q2 2026 in Review

Meridiem Capital Partners reduced its 10x Genomics (TXG) stake by 19% in Q2 2026, selling an estimated $2.67M and leaving 422,219 shares worth $16.2M. The position accounts for 0.73% of the portfolio, ranked #57.

Meridiem Capital Partners first reported a position in TXG in Q4 2024 and has held it in 3 quarters since. 390 funds tracked by Wall St. Rank hold TXG as of Q2 2026.

  • Meridiem Capital Partners held 422,219 shares of 10x Genomics worth $16.2M as of Q2 2026.
  • Meridiem Capital Partners sold 101,779 10x Genomics shares in Q2 2026, an estimated $2.67M.
  • 10x Genomics made up 0.73% of Meridiem Capital Partners's portfolio in Q2 2026, its #57 holding.
  • Meridiem Capital Partners first reported a position in 10x Genomics in Q4 2024 and has held it in 3 quarters since.
  • 390 funds tracked by Wall St. Rank held 10x Genomics as of Q2 2026.

Based on Meridiem Capital Partners's 13F filing for Q2 2026, filed 14 Aug 2026.